Dilept versus risperidone in a 28-day psychiatric comparison
Comparison in people · 2021
- What was studied
- 25 adults aged 19–54 with schizotypal disorder or pseudoneurotic schizophrenia, as described in the paper. Dilept: 15. Risperidone: 10.
- Main finding
- A WAIS-R coding task favored Dilept by 1.90 points in the authors’ analysis. The PANSS negative-symptom subscale showed no significant advantage over risperidone.
Reported findings and study design
Active-comparator study using the PANSS negative-symptom subscale, grouped psychiatric symptoms and WAIS-R testing.
Population or model 25 adults aged 19–54 with schizotypal disorder or pseudoneurotic schizophrenia, as described in the paper. Dilept: 15. Risperidone: 10.
Dose, route and schedule
Dilept 200 mg/day or risperidone 2 mg/day for 28 days. Phenazepam up to 2 mg was permitted as needed during days 1–14. From day 15, the report describes combinations with 0.5–2 mg of phenazepam.
Protocol source ↗ · Original journal abstract and comparison with the group’s 2017 and 2020 reports.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| WAIS-R digit-symbol coding | Reported difference in change −1.90 points, favoring Dilept under the authors’ sign convention | Day 28 · Reported interval −3.43 to −0.36 |
| PANSS negative symptoms and grouped psychiatric symptoms | No statistically significant between-group differences in reported changes | Day 28 |
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- Small comparison with symptom and cognitive endpoints. Benzodiazepine use complicates attribution. The paper may reuse the 15-person, 200 mg/day arm of the earlier Zakusov pilot.
Related publications may describe some of the same participants or experiments.
Source details
Original journal abstract and comparison with the group’s 2017 and 2020 reports.
Sources checked
Citation
I. O. Bogdanova, T. S. Syunyakov, G. G. Neznamov, A. A. Chepelyuk, T. V. Kovalenok, O. A. Dorofeeva. Dilept versus risperidone in a 28-day psychiatric comparison Experimental and Clinical Pharmacology. 2021;84(8):3–12.
Study source ↗ · DOI 10.30906/0869-2092-2021-84-8-3-12 · Bibliography entry · Link to this summary